Brief: Esperion Reports $156 To $160 Million In Preliminary Full-Year 2025 U.S. Net Product Sales
11/01/2026 23:04
Jan 11 (Reuters) - Esperion Therapeutics Inc ESPR.O: ESPERION PROVIDES BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ESPERION THERAPEUTICS INC - REPORTS $156 TO $160 MILLION IN PRELIMINARY* FULL-YEAR 2025 U.S. NET PRODUCT SALES Source text: ID:nGNX23vRHk Further company coverage: ESPR.O ((Reuters.briefs@thomsonreuters.com;))
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi